FDA Evaluation of Pathogen Reduction Technologies & Noncoding Regulatory RNAs in Blood Components
*Applications will be reviewed on a rolling-basis.
A research opportunity is currently available in the Office of Blood Research and Review (OBRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
The laboratory's research focus is on identifying and evaluating pathogen inactivation methods relevant to stored blood and blood components' safety, and microRNA based biomarker development for product quality.
Under the guidance of a mentor, the participant will be trained in the following research activities:
- Screening novel methods and reagents for pathogen inactivation in blood and blood components (platelets, red blood cells and plasma)
- Evaluating the effect of such treatments on the survival and function of platelets and red blood cells and plasma
- Evaluation of the treated plasma for the activities of coagulation factors
- Mitigating the adverse effects (if any) of the treatments
- Developing biomarkers of product quality following pathogen inactivation treatments
Qualifications
The qualified candidate should have received a bachelor's, master's or doctoral degree in one of the relevant fields. Degree must have been received within five years of the appointment start date.
Preferred skills:
- Hands-on experience in handling human blood and blood components, blood-borne pathogens (bacterial plating, viral assays, parasite survival assays etc.)
- Experience in small animal handling and experiments with small animals
This opportunity is available to US citizens and Lawful Permanent Residents (LPR) only.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2020-0007) in your email.